ClinicalTrials.gg
RecruitingNCT07264426Updated Nov 3, 2026

Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

An observational study in Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP and CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy), sponsored by argenx. Recruiting at 23 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by argenx · Observational

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Oct 23, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 35 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Germany — 16 open to participants now, 18 under way, 7 of them phase 3. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Germany.

Planned enrollment
2nd of 10
200 · median 79
Started
2025
with 9 others
Observational
10 of 35
7 open now
Primary completion
2029-10
later than 15 of 17 live
Registered
33rd of 35
by date
Lead sponsor
5 of 35
argenx

Among the 35 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Germany, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 10 that started in 2025, is one of 10 observational ones, reaches primary completion later than 15 of the 17 other live ones, and was the 33rd registered.

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.

Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →

Open to participants now

16 of the 35 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Germany are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 36 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies recruiting now, 24 (67%) set no upper age limit and 9 (25%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Germany, or all of them as a file.
02

Study summary

The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and assess the utilization of health care services among adult participants with CIDP who initiate treatment with efgartigimod.

As this is a noninterventional study, treatment choices and decisions will be left to the discretion of participants and their physicians, according to the standard of care.

Each participant will be prospectively followed for up to 2 years from the date of initial administration of efgartigimod.

03

Conditions studied

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • CIDP
  • CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult CIDP participants considered to be initiating efgartigimod treatment per country-specific label for the treatment of CIDP

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years at time of providing
  • Diagnosed with CIDP
  • Planned to be receiving efgartigimod treatment within the CIDP treatment label of efgartigimod in the participant's respective country
  • Efgartigimod treatment-naïve at time of screening

Exclusion criteria

Exclusion Criteria:

  • Polyradiculoneuropathy due to any other cause(s)
  • Current participation in any interventional clinical study at time of screening, or planned participation before initiation of efgartigimod
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Interventions

06

What researchers measure

Primary outcomes

  1. Change in aINCAT score over time

    The Adjusted Inflammatory Neuropathy Cause and Treatment Disability Score (aINCAT) score is a 10-point scale that covers the functionality of legs and arms. The score varies between 0 and 10 (higher score, worse outcome).

    Time frame: Up to 2 years and 3 months

  2. Change in I-RODS score over time

    Inflammatory Rasch-built Overall Disability Scale (I-RODS) assesses the limitations of activities and social participation in patients with inflammatory neuropathies like CIDP.

    Time frame: Up to 2 years and 3 months

  3. Change in grip strength over time

    Time frame: Up to 2 years and 3 months

  4. Change in EQ-5D value from index date over time

    The EQ-5D-5L questionnaire is a patient-reported outcome measure, ranging 0 to 100 (lower score, worse outcome)

    Time frame: Up to 2 years and 3 months

07

Study locations

22 of 23 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Oct 2029, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 4, 2025
StartActual
Aug 11, 2025
Primary completionEst.
Oct 2029
CompletionEst.
Oct 2029
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Alexianer St. Josef Potsdam GmbH is now Completed
Oct 23, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Alexianer St. Josef Potsdam GmbH · Potsdam, GermanyContact removed c•••@argenx.com · •••4834
  • Universitätsklinikum Frankfurt · Frankfurt, GermanyContact c•••@argenx.com · •••4834→J•••@unimedizin-ffm.de · •••3916
across 2 updates, Oct 23, 2026 – Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Universitätsklinikum Frankfurt · Frankfurt, GermanyContact c•••@argenx.com · •••4834→J•••@unimedizin-ffm.de · •••3916
  2. Oct 23, 2026
    Alexianer St. Josef Potsdam GmbH is now Completed
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Alexianer St. Josef Potsdam GmbH · Potsdam, GermanyContact removed c•••@argenx.com · •••4834
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07264426
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Dec 4, 2025
Start date
Aug 11, 2025
Primary completion
Oct 2029 (estimated)
Completion
Oct 2029 (estimated)
Last update
Nov 3, 2026

Study contacts

Sabine Coppieters, MD
Contact
clinicaltrials@argenx.com
857-350-4834

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion